Document Detail


Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands.
MedLine Citation:
PMID:  15693788     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To determine the incremental cost-effectiveness ratio (ICER) of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) vs. CHOP plus rituximab (R-CHOP) in diffuse large B-cell lymphoma (DLBCL) patients in the Netherlands. METHODS: A state transition model was developed to estimate the clinical course, costs and quality of life of patients with stage II, III or IV DLBCL receiving initial treatment with CHOP or R-CHOP to arrive at the ICER. The base year for the cost analysis was 2002 and was performed from the societal perspective. Only direct medical costs were included. The time horizon of the model was 15 yr and both costs and effects were discounted at 4%. Sensitivity analyses were performed to determine the effect of varying base-line assumptions of the model. RESULTS: The incremental gain in quality adjusted life years (QALYs) was 0.88 in both the younger and the older patient groups. The costs were 12 343 higher in the younger group of patients and 15 860 in the older patients. This resulted in an ICER of 13 983 for the younger and 17 933 for the older patients per QALY gained. These results were sensitive to the time horizon of the model, other variations had a marginal impact on the outcome. CONCLUSION: The addition of rituximab to standard therapy for DLBCL results in a gain of 0.88 QALYs. The ICER of 13 983 for younger and 17 933 for older patients per QALY gained should, seen in the light of disease severity, be considered acceptable by most policy makers in priority setting for budget allocation.
Authors:
M T Groot; P J Lugtenburg; J Hornberger; P C Huijgens; C A Uyl-de Groot
Related Documents :
19694928 - Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: effi...
17451468 - Healthcare resource utilization and costs associated with recurrent episodes of atrial ...
2126508 - Cost-benefit analysis of thrombolytic therapy.
19356388 - Pharmacist intervention in activated protein c therapy for severe sepsis: influence on ...
24497888 - Changes in patient characteristics of infective endocarditis with congenital heart dise...
12044428 - Surgical management of left ventricular aneurysms by endoventricular pericardial patch ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of haematology     Volume:  74     ISSN:  0902-4441     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-02-07     Completed Date:  2005-03-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  194-202     Citation Subset:  IM    
Affiliation:
Erasmus Medical Centre, Institute for Medical Technology Assessment, Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / economics*
Antineoplastic Combined Chemotherapy Protocols / economics,  therapeutic use
Budgets
Cost-Benefit Analysis
Decision Making
Humans
Lymphoma, B-Cell / drug therapy,  economics,  mortality
Lymphoma, Large B-Cell, Diffuse / drug therapy,  economics*,  mortality
Monte Carlo Method
Netherlands
Quality of Life
Survival Analysis
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nordic Myeloma Study Group, the first 15 years: scientific collaboration and improvement of patient ...
Next Document:  Bronchoalveolar lavage in immunocompromised patients with haematological malignancy--value of new mi...